drugset
Drugs / dendritic cell vaccine therapy
last change Sep 2022 re-read 2 minutes ago

dendritic cell vaccine therapy

also known as Dendritic Cell Therapy · CD137L-DC-EBV-VAX

Vaccine

Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma · mantle cell lymphoma · cancer · cancer of unknown primary site · follicular lymphoma · grade III lymphomatoid granulomatosis · kidney cancer · large-cell immunoblastic lymphoma
+11 more · lymphoblastic lymphoma · MALT lymphoma · marginal zone lymphoma · melanoma · nasopharyngeal carcinoma · nodal marginal zone B-cell lymphoma · primary cutaneous B-cell lymphoma · primary mediastinal large B-cell lymphoma · splenic marginal zone lymphoma · T-cell non-Hodgkin lymphoma · Waldenstrom macroglobulinemia
Investigated by
Jonsson Comprehensive Cancer Center · National Cancer Institute (NCI) · Mayo Clinic · National University Hospital, Singapore · RIZIV · University Hospital Brussels

Trials 7 · a red edge is where a trial was stopped

today NCT03035331 · Ph 1/2 NCT03282617 · Ph 1 NCT02070406 · Ph 1 NCT01697527 · Ph 2 NCT01676779 · Ph 2 NCT01239875 · Ph 0 NCT00004880 · Ph 1
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01239875 Nov 2010 → Nov 2015 MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, grade III lymphomatoid granulomatosis +6 Mayo Clinic Completed No outcome recorded
Phase 13 trials
Phase 1 NCT03282617 Aug 2017 → Aug 2019 nasopharyngeal carcinoma National University Hospital, Singapore Unknown No outcome recorded
Phase 1 NCT02070406 Jul 2014 → Dec 2018 cancer of unknown primary site Jonsson Comprehensive Cancer Center Terminated No outcome recorded
Phase 1 NCT00004880 Jun 1997 → Apr 2001 kidney cancer Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03035331 Aug 2017 → Jan 2022 T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +2 Mayo Clinic Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01697527 Nov 2012 → Nov 2026 expected cancer Jonsson Comprehensive Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT01676779 Oct 2012 → Sep 2015 melanoma University Hospital Brussels Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as dendritic cell vaccine therapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004880 ↗
3

NCT01697527 ↗

NCT02070406 ↗

NCT01239875 ↗
Known as CD137L-DC-EBV-VAX ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282617 ↗
Known as Dendritic Cell Therapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT03035331 ↗
1

NCT01676779 ↗
Action Activate “The vaccine will be made using the NY-ESO-1 protein and may help to stimulate the engineered immune response to tumor cells.” NCT01697527 ↗
Modality Vaccine “dendritic cell vaccine therapy” NCT00004880 ↗
Route Other “Given intratumorally” NCT01239875 ↗